Palliative resection of advanced primary hepatocellular carcinoma / 中国普通外科杂志

Objective　To evaluate the effect of palliative resection of advanced primary hepatocellular carcinoma (PHCC). Methods　98 patients with advanced PHCC were divided randomly into two groups in our hospital from March 1996 to Jan. 2000:(1) Therapy group (49 cases), dealt with palliative resection of liver cancer and implanted with a drug delivery system (DDS). (2) Control group (49 cases), only implanted with DDS. Results　In therapy group and control group, The decline rate of AFP was 60.0% and 31.7% respectively (P<0.05); and the survival rates of 0.5, 1, 3 　years after operation were 85.7% 　(42/49), 60.5%(23/38), 45.4%(10/22) and 　67.3%(33/49), 32.5%(13/40), 　10%(2/20) (P<0.05). Conclusions　Palliative resection of liver cancer can improve survival duration and life quality of patients with advanced HCC.

Surgical Treatment of Primary Hepatocellular Carcinoma Complicated by Intrabile Duct Obstruction / 中国医师杂志

Objective To study the diagnosis and treatment of primary hepatocellular carcinoma(HCC) complicated by intrabile duct obstruction.Methods From Aug.1994 to Feb.2000,the clinical data of 13 HCC patients with intrabile duct obstruction caused by tumor were reviewed.Results There was no operative mortality and all patients were followed up for one year.10 patients were still alive,and one died.Conclusion Jaundice caused by intrabile duct tumor was not a contraindication for hepatectomy.Hepatectomy could gain a longer postoperative survival term.

Combined superselective transcatheter arterial chemoembolization and selective intraportal venous embolization for the treatment of inoperable advanced primary liver cancer / 中国普通外科杂志

Objective To evaluate superselective transcatheter arterial chemoembolization ( TACE) plus selective portal vein embolization (SPVE) and large dose of lipiodol on advanced primary liver carcinoma (PHC).Methods Two hundred and three cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE +SPVE. Results The response rate (CR+PR) was 38% in TACE group and 59% in TACE+SPVE group (P

Clinical Investigation on Xinbao for Sick Sinus Syndrome / 中成药

Objective:To investigate the curative effect of Xinbao on patients with sick sinus syndrome(SSS). Methods: 38 patients with SSS were randomly divided into 2 groups: one (A group) taking oral Xinbao and the other (B group) taking xinxianan as control on the base of routine treament. 12 lead surface electrocardiogram and Holter were recorded in all patients before and after treatment. Results: Mean heart rates of the groups were obviously increased after treatment( P 0.05). Conclusion: Xinbao may be a effective and safe drug for treating SSS.